According to NextCell Pharma AB latest financial reports the cash on hand of NXTCL is $4.87M, an decrease of -48.49% to 2022. At the end of 2022 company had $9.45M cash on hand. This amount reflects the liquid assets available to the company, which are crucial for its operational flexibility, investment opportunities, and overall financial security.
Year | Cash on Hand | Change |
---|---|---|
2023 | $4.87M | -48.49% |
2022 | $9.45M | -30.22% |
2021 | $13.55M | 533.78% |
2020 | $2.14M | 9.09% |
2019 | $1.96M | 545.99% |
2018 | $303.30K | - |